The estimated Net Worth of Steven H Holtzman is at least $8.28 Million dollars as of 23 February 2016. Steven Holtzman owns over 579 units of Infinity Pharmaceuticals stock worth over $172 and over the last 18 years Steven sold INFI stock worth over $8,278,747.
Steven has made over 23 trades of the Infinity Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently Steven exercised 579 units of INFI stock worth $12 on 23 February 2016.
The largest trade Steven's ever made was selling 200,261 units of Infinity Pharmaceuticals stock on 29 May 2012 worth over $2,603,393. On average, Steven trades about 7,664 units every 36 days since 2006. As of 23 February 2016 Steven still owns at least 8,599 units of Infinity Pharmaceuticals stock.
You can see the complete history of Steven Holtzman stock trades at the bottom of the page.
Steven's mailing address filed with the SEC is BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON, MA, 02493.
Over the last 18 years, insiders at Infinity Pharmaceuticals have traded over $485,846,497 worth of Infinity Pharmaceuticals stock and bought 22,639,120 units worth $175,155,554 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Medical Co L.P. Rosebay. On average, Infinity Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $14,976. The most recent stock trade was executed by Adelene Q Perkins on 8 September 2023, trading 768,133 units of INFI stock currently worth $15,363.
the mission of infinity pharmaceuticals, inc. is to discover, develop, and deliver to patients best-in-class medicines for the treatment of difficult-to-treat diseases, with a strong focus in oncology and inflammation. small molecule discovery and development capabilities infinity’s programs arise from the integration of a broad range of research and development capabilities, including strengths in cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. strategic alliances building on its strengths in innovative small molecule drug discovery and development, infinity has established significant alliances with leading pharmaceutical and biotechnology companies to help realize the full potential of its product pipeline. business and scientific expertise the company has assembled a team of passionate, committed, and innovative individuals who bring together their collective expertise in all areas of business
Infinity Pharmaceuticals executives and other stock owners filed with the SEC include: